Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ · Healthcare
Amylyx Pharmaceuticals, Inc. Common Stock Total Liabilities 2021–2025
Amylyx Pharmaceuticals, Inc. Common Stock annual total liabilities history from 2021 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities as of December 31, 2025: 27.4M, a 5.14% decrease year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2025 were 27.4M, a 5.14% decrease from 2024.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2024 were 28.9M, a 65.64% decrease from 2023.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2023 were 84.0M, a 65.25% increase from 2022.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2022 were 50.8M.
Total Liabilities
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Amylyx Pharmaceuticals, Inc. Common Stock Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $27 |
| 2024 | $29 |
| 2023 | $84 |
| 2022 | $51 |
| 2021 | $17 |
Amylyx Pharmaceuticals, Inc. Common Stock Total Liabilities — FAQ
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) total liabilities over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AMLX's total liabilities history?
The chart and table above show Amylyx Pharmaceuticals, Inc. Common Stock's total liabilities by year and by quarter, including the growth rate.